Table 3.

Adverse events in patients with HER2+ breast cancer treated with lapatinib plus capecitabine (n = 26)

Adverse event	Any grade, n (%)	Grade 3–4, n (%)
Hand-foot syndrome	9 (34.5)	1 (3.8)
Diarrhea	12 (46)	2 (7.6)
Fatigue	14 (53.8)	3 (11.5)
Nausea	4 (15.3)	0 (0.0)
Rash	4 (15.4)	0 (0.0)
Anorexia	9 (34.6)	1 (3.8)
Vomiting	9 (34.6)	0 (0.0)
Stomatitis	6 (23.1)	0 (0.0)
Abdominal pain	2 (7.6)	0 (0.0)
Dyspnea	1 (3.8)	0 (0.0)
Constipation	1 (3.8)	0 (0.0)